Exelixis, Inc. (EXEL) Announces Data Presentations at ESMO 2012 Congress  
9/17/2012 9:30:09 AM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that its lead compound, cabozantinib, will be the subject of three clinical data presentations at the European Society for Medical Oncology (ESMO) 2012 Congress. During the meeting, which will be held from September 28 to October 2, 2012, in Vienna, Austria, investigators will present data from ongoing trials of cabozantinib in medullary thyroid cancer, castration-resistant prostate cancer, and non-small cell lung cancer.